SCHEMBL30484209

SCHEMBL30484209

CCCCCCc1c(C(=O)OCC)ccc(C(=O)OCC)c1C(=O)OCC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.47
ALDH1A1 P00352 4/20 0.47
LMNA P02545 1/20 0.47
TP53 P04637 1/20 0.45
CYP3A4 P08684 1/20 0.45
MAPK1 P28482 1/20 0.45
CA12 O43570 3/20 0.45
CA1 P00915 3/20 0.45
CA2 P00918 3/20 0.45
CA7 P43166 3/20 0.45
CA9 Q16790 3/20 0.45
CA14 Q9ULX7 3/20 0.45
KDM4E B2RXH2 2/20 0.43
NOD2 Q9HC29 1/20 0.43
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
HSD17B10 Q99714 2/20 0.42
POLB P06746 1/20 0.42
HTT P42858 1/20 0.41
PPARA Q07869 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9656582 1.00 TSHR (0.47) TSHRALDH1A1LMNATP53CYP3A4
SCHEMBL2975180 0.91 ALDH1A1 (0.60) TSHRALDH1A1LMNATP53CYP3A4
SCHEMBL2971967 0.91 ALDH1A1 (0.60) TSHRALDH1A1LMNATP53CYP3A4
SCHEMBL28247885 0.90 KDM4E (0.46) TSHRALDH1A1LMNATP53CYP3A4
SCHEMBL19739582 0.84 TSHR (0.59) TSHRALDH1A1LMNATP53CYP3A4
SCHEMBL11688995 0.83 TSHR (0.46) TSHRALDH1A1LMNATP53CYP3A4
SCHEMBL10601909 0.81 ALDH1A1 (0.56) TSHRALDH1A1LMNATP53CYP3A4
SCHEMBL4516539 0.81 TSHR (0.52) TSHRALDH1A1LMNATP53CYP3A4
SCHEMBL29055455 0.81 ALDH1A1 (0.56) TSHRALDH1A1LMNATP53CYP3A4
SCHEMBL10429273 0.81 ALDH1A1 (0.56) TSHRALDH1A1LMNATP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250186251-A1 OPHTHALMIC COMPOSITION AND DELIVERY DEVICE THEREOF Sydnexis, Inc. 2025-06-12 US disclosed
WO-2023069962-A1 COMPOSITIONS AND METHODS FOR MYOPIA CONTROL AND ORTHOKERATOLOGY LENSES TREATMENT OCULAR SCIENCE, INC. (US) 2023-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250186251-A1 OPHTHALMIC COMPOSITION AND DELIVERY DEVICE THEREOF CHRM3, CHRM2, CHRM4 TSHR 497/4885ALDH1A1 1558/4885LMNA 1318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.